CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 89 enrolled
Drug / intervention
300 IR grass pollen allergen extract tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00619827
NCT00619827Phase 1Completed

A Randomised, Double-blind, in Parallel Groups Placebo-controlled, Mono-centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis

Stallergenes Greer·interventional·Posted Feb 21, 2008·Updated May 23, 2016

In Brief

A Phase 1 clinical trial evaluating 300 IR grass pollen allergen extract tablet and Placebo tablet for Seasonal Allergic Rhinitis. Completed, enrolled 89 participants across 1 site.

Detailed Summary

The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after one week, one, two and four months of treatment in patients suffering from Seasonal Allergic Rhinoconjunctivitis (SAR) due to grass pollen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 21, 2008
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.4 years ago

Interventions

300 IR grass pollen allergen extract tabletdrug

300 IR grass pollen allergen extract tablet once daily during four months

Placebo tabletdrug

Placebo tablet once daily during four months